REFRESH (Completed)
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension
- Medicine
- Firibastat
- Population
- Primairy prevention cardiovasular disease
- Phase
- III
- Starting year
- 2021